Merrem and Cancidas drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Merrem (meropenem) and Cancidas (caspofungin acetate). Common drug interactions include cardiac failure congestive among females and pyrexia among males.

The phase IV clinical study analyzes what interactions people have when they take Merrem and Cancidas. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.

What is Merrem?

Merrem has active ingredients of meropenem. eHealthMe is studying from 996 Merrem users. Check the latest studies of Merrem.

What is Cancidas?

Cancidas has active ingredients of caspofungin acetate. eHealthMe is studying from 4,879 Cancidas users. Check the latest studies of Cancidas.



On Jul, 20, 2026

29 people who take Merrem and Cancidas together, and have interactions are studied.

Merrem and Cancidas drug interactions.

What are the common drug interactions of Merrem and Cancidas, by gender? *:

female:

  1. Cardiac failure congestive
  2. Cellulitis (infection under the skin)
  3. Coagulopathy (blood's ability to clot is impaired)
  4. Confusional state
  5. Death
  6. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  7. Enterobacter test positive
  8. Enterococcus test positive
  9. Febrile neutropenia (fever with reduced white blood cells)
  10. Gallbladder polyp (growths or lesions resembling growths (polypoid lesions) in the wall of the gallbladder)

male:

  1. Pyrexia (fever)
  2. Hypotension (abnormally low blood pressure)
  3. Interstitial lung disease
  4. Metapneumovirus infection (infection with human metapneumovirus)
  5. Pneumonia
  6. Pulmonary embolism (blockage of the main artery of the lung)
  7. Systemic inflammatory response syndrome (an inflammatory state affecting the whole body, frequently a response of the immune system to infection)
  8. Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
  9. Hypocalcaemia (levels of calcium in blood serum are abnormally low)
  10. Tachycardia (a heart rate that exceeds the range of 100 beats/min)

What are the common drug interactions of Merrem and Cancidas, by age (0-1 to 60+)? *:

0-1:

  1. Abdominal infection
  2. Activated partial thromboplastin time prolonged
  3. Alanine aminotransferase increased
  4. Ammonia decreased
  5. Anaemia (lack of blood)
  6. Anion gap increased
  7. Aspartate aminotransferase increased
  8. Blast cell count increased
  9. Blood albumin decreased
  10. Blood calcium decreased

2-9:

n/a

10-19:

  1. Acute lymphocytic leukaemia recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent)
  2. Blood creatinine increased
  3. Blood lactic acid increased
  4. Blood urea increased
  5. Bone marrow failure
  6. Bradycardia (abnormally slow heart action)
  7. Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
  8. Cytokine storm (over-protective immune response that can actually be fatal)
  9. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  10. Haematuria (presence of blood in urine)

20-29:

n/a

30-39:

  1. Cardiac failure congestive
  2. Death
  3. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  4. Febrile neutropenia (fever with reduced white blood cells)
  5. Multi-organ failure (multisystem organ failure)
  6. Sepsis (a severe blood infection that can lead to organ failure and death)
  7. Blood alkaline phosphatase increased
  8. Blood bilirubin increased
  9. Gamma-glutamyltransferase increased
  10. Pericardial effusion (fluid around the heart)

40-49:

  1. Multi-organ failure (multisystem organ failure)
  2. Sepsis (a severe blood infection that can lead to organ failure and death)
  3. Vascular pseudoaneurysm ruptured (leakage of arterial blood from an artery into the surrounding tissue with a continuing communication between the originating artery and the resultant adjacent cavity)
  4. Blood magnesium decreased
  5. Blood potassium decreased
  6. Cardiac arrest
  7. Dermatitis exfoliative (widespread scaling of the skin, often with itching (pruritus), skin redness (erythroderma), and hair loss)
  8. Electrocardiogram qt prolonged
  9. Rash
  10. Systemic mycosis (fungal infections of the body)

50-59:

  1. Dementia alzheimer's type (loss of mental ability with alzheimer's symptom)
  2. Dental fistula
  3. Diarrhoea
  4. Dilatation ventricular
  5. Diverticulum intestinal (a pouch that is attached to the first part of the small intestine)
  6. Dizziness
  7. Ear discomfort
  8. Ecchymosis (a discoloration of the skin resulting from bleeding underneath)
  9. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
  10. Encephalopathy (functioning of the brain is affected by some agent or condition)

60+:

  1. Hypotension (abnormally low blood pressure)
  2. Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
  3. Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
  4. Cytomegalovirus infection
  5. Cytomegalovirus test positive
  6. Diarrhoea
  7. Alanine aminotransferase increased
  8. Ascites (accumulation of fluid in the abdominal cavity)
  9. Atelectasis (partial or complete collapse of the lung)
  10. Blood alkaline phosphatase increased

What are the existing conditions these people have? *

  1. Fever: 5 people, 17.24%
  2. Hypotension (abnormally low blood pressure): 5 people, 17.24%
  3. Bacterial Infection: 5 people, 17.24%
  4. Bone Pain: 4 people, 13.79%
  5. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 4 people, 13.79%
  6. Cytomegalovirus Infection: 4 people, 13.79%
  7. Metapneumovirus Infection (infection with human metapneumovirus): 4 people, 13.79%
  8. Multiple Myeloma (cancer of the plasma cells): 4 people, 13.79%
  9. Interstitial Lung Disease: 4 people, 13.79%
  10. Pulmonary Embolism (blockage of the main artery of the lung): 4 people, 13.79%

* Approximation only. Some reports may have incomplete information.

Do you take Merrem and Cancidas?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Merrem and Cancidas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Merrem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Cancidas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Merrem and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cancidas and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on meropenem and caspofungin acetate (the active ingredients of Merrem and Cancidas, respectively), and Merrem and Cancidas (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: